Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2001-05-11
2004-02-10
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S141100, C424S155100, C424S178100, C424S184100
Reexamination Certificate
active
06689355
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to immunotherapy. More particularly, the invention relates to the use of antigen presenting cells, in particular dendritic cells, in immunotherapy.
2. Summary of the Related Art
T lymphocytes (i.e., T cells), unlike B lymphocytes (i.e., B cells), typically recognize their target antigen only when the antigen is presented in the context of the major histocompatibility complex (MHC). Thus, to present antigen to T lymphocytes, which include T helper cells and cytotoxic T cells, the antigen must be presented in context of an MHC molecule on the surface of an antigen presenting cell.
In particular, one type of antigen presenting cell, dendritic cells, has recently become of interest in the area of cancer immunotherapy. Steinman, Annu. Rev. Immunol. 9: 271-296 (1991) teaches that dendritic cells are rare leukocytes that originate in the bone marrow and can be found distributed throughout the body. Bjork, Clinical Immunology 92: 119-127 (1999) teaches that dendritic cells receive increasing attention due to their potential inclusion as biological adjuvants in tumor vaccines. Dendritic cells express several receptors for the Fc portion of immunoglobulin IgG, which mediate the internalization of antigen-IgG complexes (ICs). In this capacity, dendritic cells are used to present tumor antigens to T cells. Avigan, Blood Reviews 13: 51-64 (1999) teaches that several approaches have been adopted to directly load tumor antigens onto dendritic cells, including the pulsing of tumor peptides onto mature dendritic cells. Timmerman et al., Annu. Rev. Med. 50: 507-529 (1999) teaches that isolated dendritic cells loaded with tumor antigen ex vivo and administered as a cellular vaccine have been found to induce protective and therapeutic anti-tumor immunity in experimental animals. European Patent No. EP0553244 describes an antigen/dual-specific binding agent complex for stimulating a response to the antigen, where the binding agent specifically binds both the antigen and a cell surface receptor on an antigen-presenting cell, but where binding of the binding agent to the cell surface receptor does not block the natural ligand for the receptor.
The mechanism of action for dendritic cell antigen presentation has also been explored. Coughlan et al., Veterinary Immunology and Immunopathology 49: 321-330 (1996) discloses that antigen uptake by dendritic cells via Fc&ggr; receptors results in functional augmentation of antigen presentation and T cell proliferation in an in vitro sheep system. Regnault et a., J. Exp. Med. 189: 371-380 (1999) teaches that Fc&ggr; receptors induce dendritic cell maturation and promote efficient MHC class I-restricted presentation of peptides from exogenous, immunoglobulin (Ig) complexed antigens in the mouse system.
Thus, there remains a need to discover methods for utilizing dendritic cells to treat human diseases. The promise of dendritic cell-based approaches to treat diseases, such as cancer, underscores the need to actually develop such approaches as effective therapeutic treatments.
BRIEF SUMMARY OF THE INVENTION
The invention provides a therapeutically effective dendritic cell-based approach to the treatment of diseases associated with an antigen. The methods according to the invention comprise combining ex vivo an antigen associated with a disease and a dendritic cell binding agent specific for the antigen, with or without a dendritic cell, to provide a composition, and administering the composition to a patient having a disease associated with the antigen, wherein the composition-administered patient receives a therapeutic benefit.
Accordingly, in a first aspect, the invention provides a method for treating a patient suffering from a disease associated with an antigen, comprising administering to the patient suffering from the disease a composition comprising an antigen associated with the disease and a dendritic cell binding agent specific for the antigen, wherein the antigen is complexed to the dendritic cell binding agent and wherein the patient administered the composition receives a therapeutic benefit. Preferably, the patient is human.
In a second aspect, the invention provides a method for treating a patient suffering from a disease associated with an antigen, comprising administering to the patient a composition comprising an antigen associated with the disease, a dendritic cell binding agent specific for the antigen, and a dendritic cell autologous to the patient, wherein the patient administered the composition receives a therapeutic benefit. Preferably, the patient is a human.
In a third aspect, the invention provides a method for treating a patient suffering from a disease associated with an antigen, comprising administering to the patient suffering from the disease a composition comprising a host anti-xenotypic antibody and a xenotypic antibody specific for the antigen associated with the disease, wherein the patient administered the composition receives a therapeutic benefit.
In a fourth aspect, the invention provides a therapeutic composition comprising a purified dendritic cell binding agent that is specific for an antigen associated with a disease and the antigen associated with the disease. In preferred embodiments, binding of the dendritic cell binding agent to a receptor on a dendritic cell blocks binding of a natural ligand to the receptor. In certain embodiments of the fourth aspect of the invention, administration of the composition to a patient suffering from the disease provides the patient a therapeutic benefit. Preferably, the patient is a human. Preferably, the dendritic cell binding agent is an antibody.
In a fifth aspect, the invention provides a therapeutic composition comprising a purified dendritic cell binding agent that is specific for an antigen associated with a disease, a dendritic cell, and the antigen associated with the disease. In preferred embodiments, binding of the dendritic cell binding agent to a receptor on the dendritic cell blocks binding of a natural ligand to the receptor. In certain embodiments, administration of the composition to a patient suffering from the disease provides the patient a therapeutic benefit, wherein the dendritic cell is autologous to the patient. Preferably, the patient is human
In a sixth aspect, the invention provides a therapeutic composition comprising a purified xenotypic antibody that is specific for an antigen associated with a disease and a host anti-xenotypic antibody. In certain embodiments, administration of the composition to a patient suffering from the disease provides the patient a therapeutic benefit, wherein the dendritic cell is autologous to the patient. Preferably, the patient is human
REFERENCES:
patent: 19534630 (1997-03-01), None
patent: 0553 244 (1998-12-01), None
patent: WO 92/05793 (1992-04-01), None
patent: WO97/04802 (1997-02-01), None
patent: WO99/65517 (1999-12-01), None
patent: WO99/65523 (1999-12-01), None
Van Noort et al. International Review of Cytology, 1998.*
Steinman RM “The dendritic cell system and its role in immunogenicity” Annu Rev Immunol. 1991; 9:271-96.
Bjorck P “Development of dendritic cells and their use in tumor therapy” Clin Immunol. Aug. 1999; 92(2):119-27.
Avigan D “Dendritic cells: development, function and potential use for cancer immunotherapy” Blood Rev. Mar. 1999; 13(1): 51-64.
Timmerman JM, Levy R “Dendritic cell vaccines for cancer immunotherapy” Annu Rev Med. 1999; 50: 507-29.
Coughlan S et al., “Enhanced proliferation of CD4+ T cells induced by dendritic cells following antigen uptake in the presence of specific antibody” Vet Immunol Immunopathol. Jan. 1996; 49(4): 321-30.
Regnault A et al., “Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization” J Exp Med. Jan. 18, 1999; 189(2): 371-80.
M. Coccia et al., The Journal of Immunology, “High Titer, Prostate Specific Antigen-Specific Human IgG Production by hu-PBL-SCID Mice Immunized
Mann Dean L.
Noujaim Antoine
Schultes Birgit Corinna
AltaRex Corp.
Belyavskyi Michail A
Chan Christina
Ropes & Gray LLP
LandOfFree
Therapeutic method and composition utilizing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic method and composition utilizing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic method and composition utilizing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3341002